011000.KSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (2 5月 2024 @ 13:05):

Stats
本日の出来高	101 095
平均出来高	652 340
時価総額	193.99B
EPS	KRW0 ( 2023-09-30 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	-3.58
ATR14	KRW3.57 (0.15%)

ボリューム相関

長: -0.13 (neutral)

短: 0.00 (neutral)

Signal:(50.446) Neutral

GeneOne Life Science, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

GeneOne Life Science, 相関 - 通貨/商品

-0.34
( neutral )

-0.28
( neutral )

-0.57
( weak negative )

-0.48
( neutral )

0.46
( neutral )

GeneOne Life Science, 財務諸表

Annual	2023
収益:	KRW40.20B
総利益:	KRW-14.98B (-37.27 %)
EPS:	KRW-1 000.23

FY	2023
収益:	KRW40.20B
総利益:	KRW-14.98B (-37.27 %)
EPS:	KRW-1 000.23

FY	2022
収益:	KRW48.72B
総利益:	KRW9.34B (19.16 %)
EPS:	KRW-492.35

FY	2021
収益:	KRW38.70B
総利益:	KRW8.76B (22.63 %)
EPS:	KRW-218.13

Financial Reports:

No articles found.

GeneOne Life Science,

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.